May 12
Current report
8-K
Entered into a material agreement, Ended a material agreement
CLSDQ · Clearside Biomedical, Inc. · Documents
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date the financial statements are issued. Based on our current plans and forecasted expenses and our cash and cash equivalents, we do not believe we will be able to fund our operations for the next 12 months from the date of this filing.”View the 10-Q filed Nov 14, 2025
Market Cap
$1.30M
Shares
5.23M
Volume
—
Avg daily vol (3M)
—
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2023
May 12
Quarterly report
10-Q
FY2023 Q1, ended Mar 31
Quarterly report for FY2023 Q1
Revenue $4000
▼ 98.8%
Net loss $9.28M
Diluted EPS -$0.15
May 12
Registration statement
S-3
Registration statement
May 11
Current report
8-K
Financial results
Apr 28
Proxy statement
DEF 14A
Meeting Jun 22, 2023
Proxy statement
Apr 28
Annual report to holders
ARS
Annual report to holders
Apr 28
Proxy statement
DEFA14A
Proxy statement
Apr 18
Current report
8-K
Other events
Mar 14
Annual report
10-K
FY2022, ended Dec 31
Annual report for FY2022
Revenue $1.33M
▼ 95.5%
Net loss $32.95M
Diluted EPS -$0.55
Mar 9
Current report
8-K
Financial results
Feb 21
Current report
8-K
Events of Feb 17
Director or officer change, or executive pay
Feb 6
Current report
8-K
Events of Feb 2
Director or officer change, or executive pay
Feb 2
Current report
8-K
Financial results, Regulation FD disclosure, Other events
2022
Nov 9
Current report
8-K
Financial results, Regulation FD disclosure
Nov 9
Quarterly report
10-Q
FY2022 Q3, ended Sep 30
Quarterly report for FY2022 Q3
Revenue $266K
▼ 91.3%
Net loss $7.83M
Diluted EPS -$0.13
Aug 12
Quarterly report
10-Q
FY2022 Q2, ended Jun 30
Quarterly report for FY2022 Q2
Revenue $384K
▼ 50.8%
Net loss $7.81M
Aug 9
Current report
8-K
Financial results
Aug 8
Current report
8-K
Entered into a material agreement, Regulation FD disclosure
Jun 23
Current report
8-K
Events of Jun 22
Charter or bylaw amendment, or fiscal year change, Shareholder vote results
May 12
Quarterly report
10-Q
FY2022 Q1, ended Mar 31
Quarterly report for FY2022 Q1
Revenue $347K
▲ 920.6%
Net loss $7.64M
May 11
Current report
8-K
Financial results
Apr 29
Proxy statement
DEF 14A
Meeting Jun 22, 2022
Proxy statement
Apr 29
Proxy statement
DEFA14A
Proxy statement
Apr 19
Proxy statement
PRE 14A
Meeting Jun 22, 2022
Proxy statement
Mar 11
Annual report
10-K
FY2021, ended Dec 31
Annual report for FY2021
Revenue $29.58M
▲ 274.7%
Net income $376K
Diluted EPS $0.01
Mar 10
Current report
8-K
Financial results
Mar 3
Current report
8-K
Director or officer change, or executive pay, Regulation FD disclosure
2021
Dec 21
Current report
8-K
Regulation FD disclosure, Other events
Nov 10
Current report
8-K
Financial results
Nov 10
Quarterly report
10-Q
FY2021 Q3, ended Sep 30
Quarterly report for FY2021 Q3
Revenue $3.07M
▼ 10.4%
Net loss $4.89M
Oct 25
Current report
8-K
Regulation FD disclosure, Other events
Aug 10
Current report
8-K
Financial results
Aug 10
Quarterly report
10-Q
FY2021 Q2, ended Jun 30
Quarterly report for FY2021 Q2
Revenue $780K
▲ 120.3%
Net loss $6.1M
Jun 15
Current report
8-K
Regulation FD disclosure, Other events
Jun 10
Current report
8-K
Shareholder vote results
Jun 4
Current report
8-K
Events of Jun 2
Other events
May 17
Current report
8-K
Financial results
May 17
Quarterly report
10-Q
FY2021 Q1, ended Mar 31
Quarterly report for FY2021 Q1
Revenue $34K
▼ 99.2%
Net loss $7.35M
Apr 28
Proxy statement
DEF 14A
Meeting Jun 10, 2021
Proxy statement
Apr 28
Proxy statement
DEFA14A
Proxy statement
Mar 15
Annual report
10-K
FY2020, ended Dec 31
Annual report for FY2020
Revenue $7.89M
▲ 263.3%
Net loss $18.21M
Mar 10
Current report
8-K
Financial results
Jan 8
Current report
8-K
Events of Jan 6
Other events
Jan 5
Current report
8-K
Other events
2020
Nov 10
Current report
8-K
Financial results
Nov 10
Quarterly report
10-Q
FY2020 Q3, ended Sep 30
Quarterly report for FY2020 Q3
Revenue $3.43M
▲ 2334.0%
Net loss $2.43M
Aug 10
Current report
8-K
Financial results
Aug 10
Quarterly report
10-Q
FY2020 Q2, ended Jun 30
Quarterly report for FY2020 Q2
Revenue $354K
▲ 686.7%
Net loss $5.75M
Jun 18
Current report
8-K
Shareholder vote results
May 19
Registration statement
S-3/A
Registration statement
Showing 51–100 of 114 documents